Thursday, June 18, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Urothelial Bladder Carcinoma

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join us on Thursday, June 18
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.


Arjun Balar, MD
Associate Professor, Department of Medicine
Director, Genitourinary Medical Oncology Program
NYU Langone Health
New York, New York

Anastassia Daskalova, NP
Genitourinary Oncology, Mount Sinai
New York, New York

Peter H O’Donnell, MD
Associate Professor, Department of Medicine
Section of Hematology/Oncology
Genitourinary Oncology Program
The University of Chicago
Chicago, Illinois

Susan K Roethke, CRNP, MSN, ANP-BC, AOCNP
Genitourinary Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Module 1: Current and Emerging Role of Anti-PD-1/PD-L1 Antibodies in the Upfront Management of Advanced Urothelial Bladder Carcinoma (UBC)
  • Module 2: Optimal Application of Anti-PD-1/PD-L1 Antibodies for Patients with Relapsed/Refractory (R/R) UBC
  • Module 3: Integration of FGFR-directed Therapy into Current UBC Management Algorithms
  • Module 4: Antibody-Drug Conjugates (ADC) and Other Novel Agents in Advanced UBC

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of bladder cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Apply existing and emerging research data to the therapeutic and supportive care of patients with urothelial bladder carcinoma (UBC).
  • Identify available clinical trial data supporting the use of immune checkpoint inhibitors for the treatment of UBC to determine the current utility of these agents in clinical practice.
  • Develop an understanding of the recent revisions of the FDA approvals of atezolizumab and pembrolizumab limiting the use of these agents to patients with locally advanced or metastatic UBC who have not received prior therapy, are not eligible for cisplatin-containing treatment and who have low expression of PD-L1, to ensure safety and appropriate administration.
  • Review available and emerging clinical trial data evaluating the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated metastatic UBC (mUBC), and consider the potential role of this approach in routine practice.
  • Describe the frequency of fibroblast growth factor receptor (FGFR) abnormalities in patients with mUBC, and recognize the recent FDA approval of erdafitinib for individuals with susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with enfortumab vedotin in patients with previously treated mUBC in preparation for the potential availability of this novel compound.
  • Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immunotherapeutic strategies for mUBC, and counsel appropriately selected patients about participation in active research protocols.
  • Educate patients about the side effects and toxicities associated with approved therapies commonly employed in the management of UBC, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with UBC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

A maximum of 1.5 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Participation Completion Requirements
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by USF Health, Research To Practice (RTP) or the ANCC. Any off-label use as declared by the FDA will be identified.

Disclosure Policy
USF Health adheres to ACCME and ANCC standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made in the activity syllabus.

USF Health — USF Health CPD staff have no relevant conflicts of interest to disclose.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Equal Opportunity Statement
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.

Contact Information
If you have questions regarding credit, please contact, or call 813-224-7860.

This activity is supported by educational grants from Astellas and Seattle Genetics, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.